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IO. 
Endothelin-1 (ET-l) induced a time- and dose-dependent increase in the levels of mRNA of m2- and m,-muscarinic acetylcholine receptors 
(mAChRs) in cultured cerebellar granule cells. The levels of immunoprecipitable mj-mAChR protein and total mAChR binding sites were also 
increased by ET-l treatment. The up-regulation of m2- and m,-mAChR mRNA was blocked by phorbol ester pretreatment to inhibit ET-l-stimulated 
phosphoinositide hydrolysis and was preceded by an increase in c-fos mRNA levels. Treatments that prevented ET-l-induced c-fos mRNA increase 
also abolished the subsequent m2- and m,-mAChR mRNA up-regulation, suggesting that c-Fos protein is involved in the ET-l-induced mAChR 
expression. 
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1. Introduction 
Endothelins (ET; ET-l, ET-2 and ET-3) are a family 
of vasoconstrictive isopeptides first found to be synthe- 
sized in the endothelium (for a review, see [l]). It is now 
clear the ET peptides have a wide range of biological 
actions in both vascular and non-vascular tissues includ- 
ing the CNS [l-3]. ET-l is expressed in several brain 
areas and in neurons of spinal cord and dorsal root 
ganglia [2,3]. In cultured neurons and neurally related 
cell types, ET-l acting on specific G protein-coupled 
receptors induces a variety of intracellular events includ- 
ing phosphoinositide hydrolysis [2,4-61, an increase in 
intracellular free Ca2’ concentration [&8], the release of 
neurotransmitters [3,9], the proliferation of glial cells 
[5, lo], and the expression offis andjun proto-oncogenes 
[11,12]. 
Using cultured cerebellar granule cells as a neuronal 
model, we have previously shown that ET-1 stimulates 
phosphoinositide hydrolysis and the release of en- 
dogenous glutamate [4,9,13,14]. We have also reported 
that cerebellar granule cells express in vitro the mRNA 
for m,- and m,-muscarinic acetylcholine receptors (mA- 
ChRs) coupled to adenylate cyclase inhibition and phos- 
pholipase C activation, respectively [15,161. In addition, 
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the levels of m2- and m,-mAChR mRNA in granule cells 
are regulated by a number of drugs at both transcrip- 
tional and post-transcriptional levels [15-171. In light of 
multiple intracellular actions of ET in the nervous sys- 
tem, we examined the influence of ET-l stimulation on 
the levels of m,- and m,-mAChR mRNA in cerebellar 
granule cells. 
2. Material and methods 
2.1. Cell cultures 
Primary cultures of c-erebellar granule cells were prepared from 
I-day-old Sprague-Dawley rats, as described previously [ 161. Briefly, 
cerebella were minced and cells dissociated in 0.025% trypsin solution 
at 37°C for 15 min. The dissociation process was terminated by tritura- 
tion in Krebs-Ringer bicarbonate buffer containing 0.05% soybean 
trypsin inhibitor and 0.01% DNase. Cells were then plated at a density 
of about 10’ cells per 60-mm dish coated with poly+lysine and grown 
in basal Eagle’s medium containing 10% fetal calf serum, 2 mM glutam- 
ine, 50 PM gentamicin and 25 mM KCl. Cytosine arabinoside (10pM) 
was added 24 h after plating to inhibit the replication of non-neuronal 
cells. Cerebellar granule cell cultures were treated with indicated con- 
centrations of ET-l (Peptide Institute Inc., Osaka, Japan) after 8 days 
in vitro; at that time the cultures consisted of a highly homogenous 
population of differentiated neurons with a purity of greater than 90%. 
2.2. Northern blot hybridization 
Total RNA was -isolated from the cell lysate by centrifugation 
through 5.7 M cesium chloride to oellet the RNA. An amount of 8-10 
,ug of rota1 RNA was electrophoresed ineach lane on agarose-formalde- 
hyde gel followed by blotting to nitrocellulose membrane, as described 
previously [16]. Hybridization was performed using the RNA blot incu- 
bated at 42°C overnight with a 3*P-labeled m,-mAChR probe (0.5 kb 
AvaI fragment of human Hm2p9), an m,-mAChR probe (0.7 kb StuI- 
NheI fragment of rat Rm3p8), a murine c-fos cDNA probe, or a chicken 
B-a&in probe. High stringency washes were performed at 48°C for 15 
min in the case of m+nAChR and 56°C for m,-mAChR, c-fos and 
/9-actin. Details of the hybridization conditions, quantifications of the 
autoradiographs, and sources of various cDNA probes were as de- 
scribed [16]. 
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2.3. Immunoprecipitation assays 
Procedures for immunoprecipitation of [‘H]QNB-labeled mAChRs 
solubilized from membranes were essentially as described by Wall et al. 
[18] with slight modifications [16]. Briefly, membranes prepared from 
cerebellar granule cells were labeled with 2 nM [‘H]QNB and the 
labeled mAChRs were solubilized with 1% digitonin and 0.2% 
cholic acid. The solubilized receptors were incubated with m2- or m3- 
mAChR subtype-specific antisera kindly supplied by Dr. Barry B. 
Wolfe (Department of Pharmacology, Georgetown University School 
of Medicine, Washington, DC) for 48 h at 4°C. Bound [‘HIQNB was 
separated from free [‘H]QNB by Sephadex G-50 column chromatogra- 
phy, and the labeled receptor-antibody complex was isolated by incuba- 
tion with Pansorbin. 
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Fig. 1. Time-course of ET-l-induced increase in the levels of m,-, m3- 
mAChR mRNA, and clfos mRNA. Cerebellar granule cells after 8 days 
in culture were treated with 10 nM ET-1 for the indicated times by 
adding the peptide sequentially and terminating all reactions imultane- 
ously. (A) Autoradiographs of mRNA hybridization to cDNA of m,- 
mAChR, m,-mAChR, c-fos, and B-actin as indicated in each lane. The 
results were obtained from the same blot using different “P-labeled 
cDNA probes. (B) Densitometry of the autoradiographs. Levels of 
mRNA of m,-mAChR, m,-mAChR, and c-fos have been normalized 
to total cellular RNA present in each lane and expressed as values 
relative to their respective 0 time control. The data represent the 
means f ranges of duplicate samples. *P < 0.05; **P C 0.01 when com- 
pared with the 0 timecontrol (Student’s t-test). Similar results have been 
obtained in three independent experiments. 
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Fig. 2. Dose+ffect relationship for ET-l-induced increase of m2- and 
m,-mAChR mRNA levels. Cells were treated with indicated concentra- 
tions of ET-l for 2 h; mRNA levels for m2-, m,-mAChR, c-fos and 
B-actin were then determined. The results shown are quantified mRNA 
levels of m,- and m,-AChRs normalized to total cellular RNA and are 
expressed as the means f ranges of values relative to their respective 
controls in duplicate experiments. *P < 0.05; **P < 0.01 when com- 
pared with the untreated control (Student’s t-test). 
3. Results and discussion 
Stimulation of cerebellar granule cells with 10 nM 
ET-l produced a dose-dependent increase in levels of m2- 
and m,-mAChR mRNA (Fig. 1). The increase of m3- 
mAChR mRNA peaked at 2 h after stimulation, reach- 
ing a level approximately 260% of the 0 time control. The 
increase was still significant at 8 h (about 170% of the 
control) but returned to basal value at 24 h. The level of 
m,-mAChR mRNA was increased in parallel with that 
of m,-mAChR mRNA; however, the increase was of 
smaller magnitude and shorter lasting. We also found 
that c-fos mRNA was transiently increased by about 
2.5-fold at 30 min after ET-l stimulation. The levels of 
total RNA (which contained mostly ribosomal RNA) 
and /I-actin mRNA remained unchanged throughout the 
24-h treatment with ET-l. The ET-l-induced increase in 
m2- and m,-mAChR mRNA levels following a 2-h treat- 
ment was concentration-dependent with an EC,, value 
of approximately 5 nM (Fig. 2). At this time-point, levels 
of total RNA and mRNA of /Lactin and c-fos were un- 
changed by ET-l in the concentration range tested (l- 
100 nM) (data not shown). To assess whether levels of 
m2- and m,-mAChR protein were changed in conjunc- 
tion with an increase in m2- and m,-mAChR mRNA, 
immunoprecipitations of m2- and m,-mAChR protein 
were performed using m,- and m,-mAChR specific antis- 
era, respectively (Fig. 3). Following treatment with 10 
nM ET-l for 8 h, the level of m,-mAChR protein was 
increased to about 165% of the control; the level of 
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Fig. 3. Effects of ET-l on immunoprecipitable m2- and m,-mAChR 
protein. Cells were treated with 10 nM ET-l for 8 h and then lysed for 
preparing membranes. [3H]QNB-labeled mAChRs were solubilized 
from membranes for immunoprecipitation using m,- and m,-mAChR- 
specific antisera. Immunoprecipitable levels of m2- and m,-mAChR 
protein after ET-l treatment are expressed as percentage of untreated 
control and are the means f S.E.M. of three independent experiments. 
*P < 0.05 when compared with the respective untreated control (Stu- 
dent’s t-test). 
m,-mAChR protein showed an apparent increase but the 
change did not reach statistical significance. 
To examine the involvement of second messenger pro- 
duction in ET-l-induced increase of mAChR mRNA 
levels, phorbol ester pretreatment was employed to in- 
hibit the known ET- l-induced phosphoinositide turno- 
ver. Our results showed that a 15min pretreatment with 
500 nM phorbol dibutyrate (PDBu) attenuates ET-I- 
induced inositol phosphate accumulation in cerebellar 
granule cells by 65% [13]. Under these PDBu-pretreated 
conditions, the ET-l-induced increase of m,- and m3- 
mAChR mRNA levels was completely abolished (Fig. 
4), suggesting an essential role of phosphoinositide hy- 
drolysis in this ET-l-induced process. It should be men- 
tioned that ET-I enhances the release from cerebellar 
granule cells of [3H]D-aspartate, which labels the gluta- 
mate uptake pool [13]. This response is potentiated 
rather than inhibited by short-term PDBu pretreatment 
[13], thus indicating that the ET-l-induced mAChR 
mRNA up-regulation is unreleased to the action of re- 
leased glutamate on glutamate receptors. In support of 
this conclusion, we found that the ET-l-induced 
mAChR mRNA up-regulation was unaffected by MK- 
801, an antagonist of the N-methyl-D-aspartate subtype 
of glutamate receptors (data not shown). 
To assess the potential role of C-$X mRNA increase 
in the subsequent ET-l-induced mAChR mRNA up- 
regulation, we employed treatment with 2-aminopurine 
or cycloheximide which has been shown to inhibit the 
induction of C-$X mRNA and protein [19,20]. Confirm- 
ing these reports, we found that in cerebellar granule 
cells pretreated with 2-aminopurine (100 PM) or cyclo- 
heximide (35 PM), the induction of c-j&s mRNA at 30 
min after ET-l stimulation was completely abolished 
(Fig. 5A). Under these treatment conditions, the ET-l 
induced delayed increase of m2- and m,-mAChR mRNA 
and total mAChR binding sites were also completely 
blocked (Fig. 5B). 2Aminopurine and cycloheximide 
alone did not affect basal levels of c-fos mRNA or 
mAChR mRNA and binding sites. Interestingly, 2-amin- 
opurine in combination with ET-l decreased c-fos 
mRNA as well as mAChR mRNA and binding sites to 
levels less than those of the untreated control. Taken 
together, the close correlation between changes in c-fos 
mRNA and mAChR expression strongly suggests that 
c-fos protein induction is implicated in the transcrip- 
tional regulation of m,- and m,-mAChR mRNA. 
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Fig. 4. Effects of PDBu pretreatment on ET-l-induced mAChR mRNA 
up-regulation. Cells were pretreated with 500 nM PDBu for 15 mm and 
then stimulated with 10 nM ET-I for 2 h. (A) Autoradiographs of m,- 
and m,-mAChR mRNA as well as /3-actin mRNA. (B) Densitometry 
of the autoradiographs. Levels of m,- and m3-mAChR mRNA have 
been normalized to total cellular RNA in each lane and are expressed 
as the means + ranges of values relative to the untreated control. 
*P < 0.05; **P c 0.01 when compared with the untreated control (Stu- 
dent’s t-test). 
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Fig. 5. Effects of 2-aminopurine and cycloheximide on c-fos mRNA 
level and levels of m2- and m,-mAChR mRNA and binding sites. Cells 
were treated with 100 ,uM 2aminopurine (2-AP) or 35 PM cyclo- 
heximide (CHX) for 30 min prior to stimulation with 10 nM for 30 min 
in (A) or 2 h in (B). Levels of c-fos mRNA were determined at 30 min, 
while levels of m2- and m,-mAChR mRNA as well as total mAChR 
binding sites were determined at 2 h. mRNA levels were normalized to 
total RNA levels in each lane. The levels of total RNA or /J-actin 
mRNA were not significantly changed in our experimental conditions. 
mAChR binding sites were quantified by binding of 0.5 nM [‘H]QNB 
to intact cells grown in a 35-mm dish containing 3 x lo6 cells, as de- 
scribed previously [16]. The data are the means f ranges of values 
relative to their untreated control in duplicate experiments. Compara- 
ble results have been obtained in three independent experiments. 
*P ~0.05; **P < 0.01 when compared with the untreated control (Stu- 
dent’s t-test). The 100% value for the mAChR binding site was in the 
range of 262-279 fmoVdish of 3 x lo6 cells. 
In addition to stimulation of phosphoinositide turno- 
ver, forming inositol triphosphate and diacylglycerol, 
ET-l has been shown to induce receptor-gated Ca*’ in- 
flux in a variety of cell types [l-3, 681. The induction of 
c-fos by ET-l is therefore likely to occur via the promoter 
regulation involving the CaM kinase-Ca”/CRE or pro- 
tein kinase C-SRE pathway (for a review, see [21,22]). In 
mesangial cells, ET- 1 induces c-fos and jun gene expres- 
sion, which in turn binds to the AP-1 c&element to 
increase transcriptional activity [23]. Experiments are in 
progress to assess whether an AP-1 site-mediating mech- 
anism is involved in the ET- 1 -induced expression of mA- 
ChRs in cerebellar granule cells. The enhanced expres- 
sion of m,-mAChR mRNA and protein by ET-l may be 
physiologically significant. ET- 1 is endogenously present 
in the CNS including the cerebellum [2,3] and m,- 
mAChR is the major mAChR subtype expressed in cere- 
bellar granule cells [15,16]. Besides its robust effect in 
stimulating phosphoinositide hydrolysis [15], m3- 
mAChR mediates Ca*+ influx independent of inositol 
phosphates and intracellular Ca*’ release [24]. Thus, ET- 
l-induced expression of m,-mAChR protein may result 
in long-lasting changes in neuronal Ca*+ homeostasis 
and excitability. 
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